

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Belmonte, et al. 10 July 2008  
Serial No.: 10/565,049 Group Art Unit: 1625  
Filed: 17 January 2006 Examiner: D. O'Dell  
For: 2,2 -Substituted-3-Ethyl-Tropane Muscarinic Acetylcholine Receptor  
Antagonists (as amended)


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

FILING OF A SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. §1.97(c)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This information disclosure statement is being filed under the provisions of 37 C.F.R. §1.97(c)(2), i.e., **after** three months of the filing date of the subject application or after the mailing date of the first Office Action on the merits, whichever event occurred last but **before** the mailing date of either a Final Action under 37 CFR §1.113 or a Notice of Allowance under 37 CFR §1.311, along with authorization to charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,



Dara L. Dinner  
Attorney for Applicants  
Registration No. 33,680

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5017  
Facsimile (610) 270-5090